The discovery of a selective, high affinity A2B adenosine receptor antagonist for the potential treatment of asthma
- 1 February 2005
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 15 (3) , 609-612
- https://doi.org/10.1016/j.bmcl.2004.11.044
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- CVT-4325: a potent fatty acid oxidation inhibitor with favorable oral bioavailabilityBioorganic & Medicinal Chemistry Letters, 2004
- Adenosine-Activated Mast Cells Induce IgE Synthesis by B Lymphocytes: An A2B-Mediated Process Involving Th2 Cytokines IL-4 and IL-13 with Implications for AsthmaThe Journal of Immunology, 2004
- Design, Synthesis, and Biological Evaluation of New 8-Heterocyclic Xanthine Derivatives as Highly Potent and Selective Human A2BAdenosine Receptor AntagonistsJournal of Medicinal Chemistry, 2004
- A2BAdenosine Receptors Increase Cytokine Release by Bronchial Smooth Muscle CellsAmerican Journal of Respiratory Cell and Molecular Biology, 2004
- Anilide Derivatives of an 8-Phenylxanthine Carboxylic Congener Are Highly Potent and Selective Antagonists at Human A2B Adenosine ReceptorsJournal of Medicinal Chemistry, 2000
- Theophylline RevisitedAllergy and Asthma Proceedings, 1996
- Theophylline toxicity in children: A retrospective reviewPediatric Emergency Care, 1993
- Aminophylline loading in asthmatic patients: A protocol trialAnnals of Emergency Medicine, 1989